Husk at jeg skrev også:
(Ny uthevning)
Det overrasket meg, men den ene eller andre av disse store eierne er vel like gode. Og transaksjon ble også gjort til mer eller mindre markedskurs, så det er jo ingen dumping fra Holta som man ellers kunne fryktet ville presset kursen lenge.
Noen med tilgang?
We are excited to welcome you to the first newsletter of 2025! As we look back on a transformative 2024, it’s clear that the awareness of the clinical impact of circulating calprotectin continues to grow. We have expanded our clinical collaborations, with both prospective and retrospective studies already underway in 2025.
The increasing global demand has driven routine clinical adoption and a surge in scientific evaluation across a range of inflammatory conditions.
Calprotectin, a neutrophilic heterodimer comprised of S100A8 and S100A9, is released as part of the innate immune response. Its rapid release and direct correlation with inflammation make it a reliable marker across various infectious, autoimmune, and autoinflammatory conditions.
Calprotectin’s ability to accurately track even subclinical inflammation is making it invaluable in monitoring inflammatory rheumatic diseases (IRDs), including rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). A continuously growing body of scientific evidence, supported by multiple clinical trials, has led to inclusion of calprotectin measurements in guidelines issued by EULAR, ACR, and PReS.
Calprotectin is also emerging as a valuable biomarker in emergency medicine, offering early detection of bacterial infections due to its rapid kinetics and release into circulation, even before systemic inflammatory responses develop.
This webinar provides an overview of the many options for use of serum calprotectin in adult and paediatric patients suffering from autoinflammatory diseases such as rheumatoid arthritis, Still’s disease, vasculitis, and juvenile idiopathic arthritis (JIA).
We are pleased to announce the launch of the GCAL® Calprotectin Immunoassay with Beckman Coulter Diagnostics to its clinical chemistry platforms. This partnership marks an important development for the calprotectin testing market, bringing this innovative biomarker to a broad audience and ensuring easy and fast routine access for laboratories and clinicians.
Recent studies highlight calprotectin’s potential in predicting treatment response for RA and JIA, supporting its role as a key biomarker. Recent publications demonstrate how calprotectin measurements aid in optimising treatment decisions and monitoring disease activity.
CORA 2025 - International Congress on Controversies in Rheumatology and Autoimmunity
ISICEM 2025 – International Symposium on Intensive Cardiovascular Care
21st International Vasculitis Workshop (2024) outcome
Fremdeles ganske så illikvid denne, og lite endringer på aksjonærlistene. Alliekvel hyggelig at Dukat AS øker med en håndfull aksjer til totalt 80k.
Join us at National Kidney Foundation hashtag#NKFClinicals to learn more about hashtag#cystatinC and why two biomarkers are better than one in hashtag#kidneyhealth. Combining cystatin C with creatinine can improve diagnostic accuracy and support better clinical decisions.
You find us at booth #921
Visit us to learn about Gentian’s Cystatin C assay, designed for easy and fast integration into existing lab workflows. Our cystatin C team will be ready to answer your questions!
The Company’s nomination committee proposes that the general meeting resolves to elect the
following chairperson and members to the board of directors until the annual general meeting in
2026:
a. Hilja Ibert, non-executive, independent chairperson (re-election)
b. Kari E Krogstad, non-executive, independent board member (re-election)
c. Kjersti Grimsrud, non-executive, independent board member (re-election)
d. Runar Vatne, non-executive, board member (new election)
e. Christian Åbyholm, non-executive, board member (new election)
Da blir dermed de to største eierne av Gentian direkte representert i styret. Vatne med 13,68% og Åbyholm representerer 22.2% av aksjene i selskapet. Totalt 35,88%.
Elypta, the Swedish company pioneering metabolism-based early cancer detection, is pleased to announce the appointment of Dr. Hilja Ibert to its Board of Directors. Hilja brings extensive leadership experience in the diagnostics industry and a strong track record of commercial success.
“ Hilja’s deep expertise in commercializing diagnostics will be invaluable as we aim to launch our first diagnostic products next year ,” says Elypta CEO Karl Bergman.
Dr. Ibert has over 30 years of experience in clinical diagnostics, having held senior positions at international companies, including Hologic, Becton Dickinson, and bioMérieux. She recently served as CEO and now chairs the Board of Gentian Diagnostics ASA, where she played a key role in the company’s growth and success. She is also a board member at Gradientech, a company specializing in ultra-rapid antibiotic susceptibility testing, and VitaDx, a pioneer in AI and image processing in the field of cytology for cancer diagnostics
Hadde ikke fått med meg Kari Krogstad i styret (ihvertfall ikke husket), men det er jo definitivt en person med fantastisk relevant erfaring og track record.
Styremedlem Grimsrud (sittet 1 år?) nylig innside kjøpt 10k aksjer på +46 kr. I etterkant av Andenæs mega kjøp på 46.5 kr i februar. Tyder på godt driv 
We are excited to announce the relaunch of www.calprotectin.com – our dedicated resource hub on circulating hashtag#calprotectin for healthcare and laboratory professionals working in the field of inflammatory hashtag#rheumaticdiseases.
Gentian’s calprotectin assay - GCAL® - is intended to be used as an aid in detection and assessment of autoimmune diseases:
Fast – Enables rapid and sensitive detection of inflammation
Direct – Marker of disease activity
Easy – Measured through a routine blood test using standard clinical chemistry platforms
Discover how GCAL® – Gentian’s serum and calprotectin assay – enables automated, high-throughput measurement of calprotectin on major clinical chemistry analysers.
